As a result of their ability to effectively reduce the risk of skeletal-related events, bisphosphonates (BPs) were incorporated into clinical practice over a decade ago, leading to a new treatment paradigm for patients with skeletal involvement from advanced cancer. BPs are now a well-established treatment option in this setting. Our review of the literature found that in addition to maintaining bone health in patients with malignant bone lesions and patients at risk for cancer therapy-induced bone loss, emerging preclinical and clinical data suggest that BPs may also have anticancer activity. Later generation, nitrogen-containing BPs (N-BPs), such as zoledronic acid (ZOL), inhibit the mevalonate pathway, subsequently inhibiting a number of cellular functions in bone-resorbing osteoclasts. In addition, N-BPs inhibit cancer cell proliferation, viability, motility, invasion and angiogenesis; induce cancer cell apoptosis; and act in synergy with antineoplastic agents. N-BPs, especially ZOL, may be useful as anticancer agents. As evidence continues to emerge, another shift in cancer treatment paradigms, in which N-BPs are considered for their anticancer activity as well as palliative effects, may be approaching.
Introduction
Prostate cancer is the second most prevalent malignancy in men worldwide, 1 with an estimated 217 730 new cases diagnosed in the United States alone in 2010. 2 Primary treatment for men diagnosed with high-risk disease includes surgery or radiation therapy. Following primary therapy, disease progression is monitored by measuring PSA levels. If these levels remain elevated or increase after primary treatment, androgen-deprivation therapy may be considered to lower testosterone levels. 3 However, androgen-deprivation therapy may lead to adverse effects on bone health, including osteoporosis and increased incidence of fractures. 3 Furthermore, advanced cancer itself can have detrimental effects on bone.
There is a high rate of metastasis to bone among patients with advanced prostate cancer. Bone metastases disrupt the normal homeostasis between osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells) and weaken the skeleton. 4 Moreover, patients with bone metastases are at risk for skeletal-related events (SREs) such as pathologic fractures, spinal cord compression, hypercalcemia, the need for surgery to bone, or severe bone pain requiring palliative radiotherapy or changes in antineoplastic therapy. In the absence of antiresorptive therapy, approximately 50% of patients with bone metastases from prostate cancer will experience an SRE during their disease course. 5 As a result of their ability to effectively reduce the risk of SREs, [5] [6] [7] [8] bisphosphonates (BPs) were adopted as a standard supplemental therapy for patients with advanced cancer.
BPs are a well-established treatment option for maintaining bone health in patients with cancer. 9 The relative efficacy of these agents to delay the onset and reduce the risk of potentially debilitating SREs depends primarily on their chemical structure. All BPs accumulate in the mineral portion of the bone matrix and are released during bone resorption. First-generation BPs, such as clodronate, do not contain nitrogen and are metabolized by osteoclasts into nonhydrolyzable cytotoxic adenosine triphosphate analogues. 10, 11 In contrast, nitrogen-containing BPs (N-BPs) inhibit the mevalonate pathway after internalization by osteoclasts. 10, 11 Among the more active N-BPs, zoledronic acid (ZOL) is the only BP indicated for the treatment of patients with bone metastases from all solid tumors, including prostate cancer. 3, 12 In addition to the established use of N-BPs to preserve skeletal integrity, emerging preclinical and clinical evidence supports their anticancer activity. An intriguing hypothesis for a mechanism of N-BP anticancer activity is that BPs render the bone marrow microenvironment less suitable for the growth of tumor cells. 13 N-BPs may target several steps involved in the metastatic process, including tumor cell growth, migration, adhesion to extracellular matrix, extravasation into distant tissues, angiogenesis and avoidance of immune surveillance. 14, 15 Furthermore, N-BPs have demonstrated synergistic anticancer activity when used in combination with anticancer agents in the preclinical setting, and clinical investigations to further explore this synergy are ongoing. 15 Thus, as evidence continues to emerge, another treatment paradigm shift may be approaching for the use of N-BPs as anticancer therapy.
Antiresorptive mechanism of action
BPs are stable pyrophosphate analogues that bind to bone surfaces with high affinity.
14 Once internalized, N-BPs affect multiple pathways, resulting in their effective antiresorptive activity; the known mechanism of action for this bone-resorbing activity is through inhibition of the mevalonate pathway in osteoclasts. 14 The mevalonate pathway is an important biochemical pathway involved in the production of cholesterol and isoprenoids, which are required for maintaining cellmembrane integrity, producing steroids and regulating cellular respiration. 16 Furthermore, isoprene precursors are crucial for the prenylation of regulatory proteins involved in the control of cell proliferation, tumor progression and cell death induced by anticancer therapies. 16 Thus, inhibition of the mevalonate pathway may have an impact on cellular activities that goes beyond inhibition of bone resorption.
N-BPs, including ZOL, inhibit farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway required for the post-translational modification and function of small GTPases (for example, Ras, Rho, Rac), which have a key role in cell proliferation and survival. The ability of various N-BPs to inhibit farnesyl pyrophosphate synthase activity correlates with their relative potency. In preclinical model systems, ZOL was the most potent inhibitor of farnesyl pyrophosphate synthase activity among the N-BPs tested, and ZOL correlated with the greatest antiresorptive activity. 10, 17 In addition to inhibiting farnesyl pyrophosphate synthase, N-BPs induce the production of an intracellular adenosine triphosphate analogue (triphosphoric acid 1-adenosin-5 0 -yl ester 3-(3-methylbut-3-enyl) ester [ApppI] ) that can directly induce cellular apoptosis. As a result, N-BPs interfere with multiple cellular functions required for the bone-resorbing activity and survival of osteoclasts. Moreover, the cellular functions affected by N-BPs may be involved in cancer cell growth as well as osteoclast survival.
Preclinical evidence of potential anticancer activity
Preclinical evidence suggests that N-BPs exhibit anticancer activity and can inhibit multiple steps in the metastatic pathway. Among N-BPs, the anticancer activity of ZOL has been examined extensively in preclinical models of prostate cancer (Table 1) . [18] [19] [20] [21] [22] [23] [24] [25] [26] Moreover, the anticancer activity of ZOL can be direct (inhibiting cancer cell growth and survival) or indirect (effects on cancer cell invasion, angiogenesis or activation of the immune system).
Direct anticancer effects
Preclinical studies show that ZOL can inhibit the survival and proliferation of cancer cells directly. In a study examining cancer cell growth and viability, ZOL reduced the survival and proliferation of both androgendependent (LNCap and LNCap C4-2B) and androgenindependent (PC3 and DU145) prostate cancer cell lines. 24 In the same study, ZOL reduced interleukin-6 expression and inhibited nuclear localization of nuclearfactor kappa-B. 24 In another study, ZOL-mediated induction of apoptosis and inhibition of adhesion of prostate cancer cells was shown to be dependent on its ability to inhibit the mevalonate pathway and consequently block protein prenylation. 21 Taken together, these data suggest that the observed effects of ZOL on Bisphosphonates as potential anticancer agents HK Koul et al cancer cell growth and viability may occur through inhibition of transcription factors involved in the modulation of the immune response and/or by inhibition of the mevalonate pathway. Moreover, the anticancer activity of ZOL observed in vitro translates to in vivo effects. For example, in vivo experiments showed that ZOL reduced tumor growth in osteolytic and osteoblastic metastases in a mouse model of prostate cancer. 20 However, ZOL treatment did not affect subcutaneously implanted xenografts. Another mouse model of prostate cancer showed that ZOL, separately or in combination with an antibody against human platelet-derived growth factor receptor alpha, prolonged survival and significantly slowed growth of skeletal metastases. 25 Taken together, these preclinical data indicate that ZOL may directly inhibit tumor growth within the bone and may prolong survival in vivo. The restriction of BP activity to the bone is not necessarily a limitation, as the immune and vascular components that reside within this niche are key determinants of cancer progression and recurrence. Indeed, it has been shown that the activity and function of various hematopoietic cells may potentially be modified by BPs and these activities may extend outside of the bone, possibly because cells of hematopoietic lineage eventually enter the systemic circulation. 27, 28 In addition, the recent success in approaches using a liposome-encapsulated BP such as ZOL to extend plasma half-life and enhance anticancer activity may further the therapeutic value of this drug. 29 However, it should be noted that this would entail early phase clinical development to establish the pharmacokinetics and safety of these new formulations.
As many studies use high doses of N-BP, the clinical relevance of these findings is unknown. However, anticancer activity also has been demonstrated in preclinical studies using clinically relevant doses of ZOL in combination with other anticancer agents in prostate cancer cell lines. 23, 26 Androgen-independent prostate cancer cells (PC3) that were treated with clinically achievable concentrations of ZOL (1 mM), or docetaxel (3 nM), or both in combination, significantly reduced prostate cancer cell viability and increased apoptosis (both Po0.003). 23 Notably, docetaxel was not as effective as ZOL in reducing cell viability or increasing apoptosis. Furthermore, adding docetaxel to ZOL had no impact on the activity against prostate cancer cells observed with ZOL alone, suggesting that the cytotoxic activity of ZOL was equivalent or superior to docetaxel in this study. 23 Similarly, clinically relevant doses of ZOL (25 mM) in combination with docetaxel (1 ng ml -1 ) significantly reduced PC3 cell viability (Po0.05). 26 Furthermore, the administration of both drugs together resulted in synergistic activity compared with docetaxel alone. These data suggest that the observed anticancer activity of ZOL occurs at clinically relevant concentrations, and that the activity is comparable to that of a conventional chemotherapeutic agent, docetaxel.
ZOL also has shown synergistic activity with cytotoxic agents in breast cancer and prostate cancer model systems. 22 In one study, breast cancer and prostate cancer cell lines were treated with ZOL alone, doxorubicin alone or both in sequence (doxorubicin followed by ZOL or ZOL followed by doxorubicin). 22 Clinically relevant concentrations of doxorubicin (0.05 mM) followed by ZOL (25 mM) 24 h later induced apoptosis of breast cancer and prostate cancer cells in a synergistic fashion (P ¼ 0.004). 22 The observed sequence-dependent induction of apoptosis was dependent on the mevalonate pathway, as rescue of inhibition of this pathway prevented apoptosis by doxorubicin and ZOL in sequence. 22 These data suggest that the anticancer activity observed with ZOL in combination with other cytotoxic agents is more than merely additive, and may in fact be synergistic.
Indirect anticancer effects
In addition to direct effects on cancer cells, preclinical studies show that ZOL can inhibit cancer cell invasion, decrease angiogenesis and activate the immune system. 18, 19, [30] [31] [32] [33] [34] [35] [36] Two studies have shown that ZOL inhibits breast cancer and prostate cancer cell line invasion, an early event in the formation of bone metastases. 18, 30 In a Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) invasion assay, pretreatment of highly metastatic breast cancer (MDA-MB-231) and prostate cancer (PmPC3) cell lines with BPs (ZOL, ibandronate and clodronate) inhibited cancer cell invasion. 18 Notably, ZOL was the most active of the BPs tested. Another study utilizing a Matrigel invasion assay showed that ZOL inhibited invasion of a highly metastatic breast cancer (of MDA-MB-231) cell line. 30 Inhibition occurred through disorganization of the actin cytoskeleton caused by defective prenylation of RhoA, adding to the evidence supporting inhibition of the mevalonate pathway as a potential mechanism of action for the anticancer activity of ZOL. These data suggest that ZOL may prevent metastasis of breast cancer or prostate cancer cells by preventing cell invasion.
In vitro and in vivo studies show that ZOL can inhibit several steps involved in angiogenesis, 19, 31 an important process involved in cancer cell growth. In vitro, ZOL inhibited proliferation, adhesion and migration of stimulated human endothelial cells and reduced blood vessel sprouting in cultured aortic ring and chicken chorioallantoic membrane assays. 31 In addition to these effects observed in vitro, ZOL also inhibited angiogenesis in mice. 31 Another study showed that BPs (ZOL, ibandronate, risedronate and clodronate) decreased proliferation and capillary-like tube formation and induced apoptosis in human endothelial cells. 19 These results translated in vivo, wherein BPs including ZOL reduced revascularization of the prostate gland in castrated rats treated with testosterone. 19 Interestingly, in another in vivo study, it was shown that ZOL suppressed pro-angiogenic MMP-9 expression in macrophages infiltrating tumor sites and reduced association of vascular endothelial growth factor with endothelial cells. 37 These data indicate that ZOL can inhibit angiogenesis in vitro and in vivo, suggesting another potential mechanism of action for the anticancer activity demonstrated by ZOL.
Preclinical studies suggest that another potential mechanism of action for the observed anticancer activity of ZOL may be through activation of the immune system against cancer cells. Recent preclinical evidence supports the ability of BPs to activate gamma-delta (gd) T cells, which are a subset of T cells with anticancer activity. Data from these preclinical studies suggest several possible mechanisms of action of ZOL for the anticancer activity observed in translational and clinical studies. Moreover, current evidence suggests that the observed preclinical anticancer activity of N-BPs may translate into clinical benefits. Clinical study data support the hypothesis that ZOL may provide additional benefits beyond preservation of skeletal health in patients with prostate cancer (Table 2) . [38] [39] [40] [41] [42] [43] Data from multiple small translational studies also suggest that BPs influence key steps in the growth and progression of cancer by inhibiting angiogenesis, enhancing host-mediated anticancer activity and eliminating residual cancer cells from the bone marrow.
Inhibition of micrometastases
One possible mechanism of ZOL anticancer activity may be through its effect on disseminated tumor cells, which can seed subsequent metastases or local recurrence. 14, 44 Circulating tumor cells often adhere to the bone marrow microenvironment, which provides a rich supply of nutrients and growth factors that facilitate cell survival, differentiation and proliferation. Once tumor cells stop circulating to reside in the bone marrow, they become disseminated tumor cells and can potentially initiate bone metastases. The bone marrow microenvironment provides a secure niche for disseminated tumor cells to survive, allowing them to evade the cytotoxic effects of systemic anticancer therapy. 14, 45, 46 Studies have shown that ZOL reduces the number and persistence of disseminated tumor cells in the bone marrow of patients with breast cancer. [47] [48] [49] [50] Persistence of disseminated tumor cells after radical prostatectomy in patients with no evidence of disease was an independent predictor of disease recurrence, suggesting that disseminated tumor cells may be clinically significant. [51] [52] [53] Moreover, persistence of circulating tumor cells and disseminated tumor cells has been associated with an increased risk of recurrence and distant metastases in patients with prostate cancer. [51] [52] [53] [54] [55] Thus, ZOL may be able to prevent distant metastases and local recurrence by decreasing the persistence of circulating tumor cells and disseminated tumor cells.
Stimulation of antitumor immune response
Translational studies demonstrated that ZOL stimulated the activity of circulating gd T cells in patients with prostate cancer 42 and breast cancer. 56 Comparing blood samples from patients with prostate cancer (N ¼ 11) before and after treatment with ZOL showed that peripheral blood gd T cells were activated by ZOL. 42 Furthermore, serum PSA levels decreased in 3 of 11 patients and PSA velocity decreased in 5 of 10 patients with prostate cancer after receiving ZOL. 42 In another study, blood samples obtained from patients with early breast cancer (N ¼ 23) before and after (7, 28, 56, 90 and 180 days) a single dose of ZOL (4 mg) showed that ZOL activated effector subsets of gd T cells. 56 These data indicate that ZOL may be able to activate the immune system to selectively target and kill some cancer cells and improve clinical outcomes.
Antiangiogenic effects
In addition to affecting the immune response, ZOL can modulate levels of vascular endothelial growth factor, which is required for angiogenesis. A translational study showed that ZOL significantly reduced circulating vascular endothelial growth factor levels in patients with bone metastases from solid tumors (N ¼ 26), including breast cancer and prostate cancer. 57 Furthermore, this effect persisted through 28 days of ZOL therapy (1 mg every week for 4 weeks; P ¼ 0.008) and during the 3 months of the second phase of ZOL therapy (4 mg every 4 weeks for 12 weeks). 57 Therefore, part of the anticancer activity observed for ZOL may be via inhibition of angiogenesis by decreasing vascular endothelial growth factor levels. 40 Patients received either docetaxel first followed by ZOL the next day (sequence A, n ¼ 10) or ZOL first followed by docetaxel the next day (sequence B, n ¼ 12). 40 For patients who received docetaxel followed by ZOL, 66.7% of patients had an objective response and stable disease. Furthermore, PSA levels decreased by 450% in four patients who received docetaxel followed by ZOL. No anticancer activity was observed in patients who received sequence B, ZOL followed by docetaxel, 40 confirming the importance of sequencing observed in preclinical studies.
In addition, retrospective analyses suggest that ZOL may improve cancer-related outcomes in patients who potentially benefit from improvement or stabilization of skeletal health. For example, in retrospective analyses of the phase III clinical trials of ZOL it was shown that ZOL-mediated normalization of bone markers was associated with improved survival in patients with bone metastases from solid tumors, including castrationresistant prostate cancer (n ¼ 472, castration-resistant prostate cancer subset; Figure 1) . 39 Further, in a retrospective database analysis ZOL improved overall survival in patients with bone metastases from prostate cancer compared with patients who did not receive BPs. 41 It could be argued that the survival benefits observed in these analyses may be because of improved skeletal health and quality of life that allow better compliance with primary anticancer therapy.
Clinical trials
Although clinical data regarding the anticancer activity of BPs in prostate cancer are limited, a few trials have examined the anticancer activity of clodronate in patients with prostate cancer. An interim analysis of a study in patients with high-risk prostate cancer (N ¼ 140) showed that patients who received intravenous clodronate every 3 months had significantly longer (sevenfold) time to development of bone metastasis compared with placebo (Po0.001). 58 Furthermore, the final analyses of long-term survival data from the PR04 and PR05 studies in patients with nonmetastatic and metastatic prostate cancer, respectively, showed that oral clodronate (8320 mg day -1 ) improved overall survival in patients with metastatic prostate cancer (n ¼ 278; hazard ratio (HR) ¼ 0.77; P ¼ 0.032), but not nonmetastatic prostate cancer (n ¼ 471; HR ¼ 1.12; P ¼ 0.94) compared with placebo. 59 Together, these data suggest that BPs may have anticancer activity in patients with prostate cancer. Moreover, clinical data supporting the anticancer activity of more active N-BPs in other tumor types may translate to patients with prostate cancer.
Several large clinical trials in patients with breast cancer support the emerging role of ZOL as an anticancer agent and provide the rationale to continue investigations into this therapeutic potential. The Zometa-Femara Adjuvant Synergy Trials (Z-/ZO-/E-ZO-FAST) are companion trials in postmenopausal women receiving adjuvant hormonal therapy for early breast cancer. All three trials showed improved bone mineral density with upfront ZOL, [60] [61] [62] whereas the Z-FAST and ZO-FAST trials demonstrated improved survival in patients who received upfront ZOL compared with delayed ZOL. 61, 63 The ZO-FAST trial (N ¼ 1065) showed a 41% improvement in disease-free survival (P ¼ 0.0314) and demonstrated a decrease in local and distant disease recurrence in and outside of bone at 36 months' median follow-up. 61 The disease-free survival benefit with upfront ZOL versus delayed ZOL continued through 60 months of follow-up. 64 A similar trend was observed at the 36-month update of the Z-FAST study. 60 Furthermore, a 24-month integrated analysis of the Z-/ZO-FAST trials (N ¼ 1667) showed that upfront ZOL increased diseasefree survival by 43% (HR ¼ 0.573; P ¼ 0.0183) compared with delayed ZOL. 63 However, in the E-ZO-FAST trial (N ¼ 527) there were no significant differences in proportions of patients with disease-free survival events for upfront versus delayed ZOL (P ¼ 0.1397) after 36 months' follow-up. 65 In addition to the Z-/ZO-FAST trials, the ABCSG-12 study in premenopausal women with early breast cancer (N ¼ 1803) showed that ZOL in combination with endocrine therapy reduced the risk of disease-free survival events by 36% (P ¼ 0.01), decreased the relative risk of disease progression by 33% (P ¼ 0.02) and decreased the risk of recurrence in and outside of bone by 32% (P ¼ 0.03) compared with endocrine therapy alone. 66 Moreover, ZOL continued to reduce the risk of disease-free survival events by 32% (HR ¼ 0.68; P ¼ 0.009) over 2 years after therapy completion (median follow-up of 62 months). 67 In the AZURE study, women with breast cancer (N ¼ 3360) received standard therapy alone or standard therapy plus ZOL. 68 Although the adjuvant use of ZOL did not improve disease-free survival (primary 
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Bisphosphonates as potential anticancer agents HK Koul et al endpoint) in the overall patient population (HR ¼ 0.98; P ¼ 0.79), there was a trend toward improved overall survival for ZOL versus control in the overall population (HR ¼ 0.85; P ¼ 0.07). 68 Furthermore, a prospective protocol-defined subgroup analysis based on menopausal status showed that ZOL significantly improved diseasefree survival (HR ¼ 0.76; Po0.05) and overall survival (HR ¼ 0.71; P ¼ 0.017) in patients who were 5 or more years postmenopausal at baseline. 68 It is important to note that the premenopausal populations in the ABCSG-12 and AZURE trials were markedly different. In ABCSG-12, premenopausal women underwent ovarian ablation with goserelin therapy plus either anastrozole or tamoxifen that resulted in endocrine therapy-induced menopause, whereas almost no premenopausal women in the AZURE study received hormonal therapy.
Furthermore, in the neoadjuvant subset analysis (n ¼ 205) of the ongoing AZURE trial, ZOL in combination with chemotherapy significantly reduced the residual invasive tumor size by 43% (P ¼ 0.006) and almost doubled the pathologic complete response compared with neoadjuvant therapy alone. 69 The evidence of anticancer activity derived from this neoadjuvant setting is particularly relevant because it reflects data derived from patients treated for a relatively short period and is not confounded by benefits in reduced risk of skeletal events. Thus, three large phase III clinical trials show that ZOL improves clinical outcomes and supports the use of ZOL as an anticancer agent in patients with early breast cancer. The data from these large, prospective clinical trials suggest that ZOL may have anticancer activity in the adjuvant cancer setting.
Clinical data also have emerged from studies in patients with cancer types other than breast cancer in the advanced disease setting. In patients with bone metastases from bladder cancer (N ¼ 40), ZOL significantly increased the 1-year overall survival rate (36% versus 0%; P ¼ 0.004) and improved SRE-free survival (P ¼ 0.001) compared with placebo. 70 A clinical trial in patients with bone metastases from non-small cell lung cancer (N ¼ 144) showed that ZOL significantly increased overall survival compared with no ZOL (Po0.01). 71 Moreover, this study showed that persistence in ZOL therapy led to significantly improved survival and longer time to progression (both Po0.01). 71 In a small clinical trial, significantly more patients with recurrent or advanced metastatic cancer (multiple types) without evidence of bone metastases (N ¼ 40) who received ZOL remained free of bone metastases at 12 months compared with no ZOL (60% versus 10%, respectively; Po0.0005).
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Furthermore, in the first large study investigating anticancer effects of BPs in patients with multiple myeloma (MRC Myeloma IX study; N ¼ 1960), ZOL significantly improved overall survival by 16% (HR ¼ 0.842; P ¼ 0.0118) and disease progression compared with clodronate (HR ¼ 0.883; P ¼ 0.0179). 73 Overall, clinical data suggest that ZOL has anticancer activity and would be a useful addition to current therapeutic regimens.
Ongoing clinical trials
Ongoing clinical trials examining the potential anticancer activity of ZOL in patients with prostate cancer include TRAPEZE, STAMPEDE, RADAR and ZEUS. [74] [75] [76] [77] Overall and disease-free survival are secondary outcome measures in the TRAPEZE trial (ISRCTN12808747), which is examining the safety and feasibility of administering docetaxel therapy in combination with ZOL and strontium-89 to patients with castration-resistant prostate cancer. 74 The STAMPEDE trial (ISRCTN78818544) is assessing the anticancer activity of ZOL in patients with locally advanced or metastatic prostate cancer, 77 and the RADAR study is evaluating if ZOL can prevent bone loss and bone metastases in patients with prostate cancer initiating androgen-deprivation therapy. 76 Finally, the ZEUS study is examining the ability of ZOL to prevent bone metastases in patients with asymptomatic recurrent prostate cancer. 75 
Novel agents
More recently, denosumab, a fully human monoclonal antibody that neutralizes RANK ligand, was approved for the prevention of SREs in patients with bone metastases from solid tumors. In part, this approval was based on data from a phase III trial in patients with bone metastases from castration-resistant prostate cancer, in which denosumab demonstrated non-inferiority to ZOL in delaying time to first SRE. 78 Investigations into the ability of denosumab to delay disease progression are also ongoing in multiple cancer types, including prostate cancer. A recent trial investigated the potential clinical utility of denosumab for the prevention of bone metastases, a major cause of morbidity and mortality, in patients with castration-resistant prostate cancer. 43 This placebocontrolled, randomized trial enrolled patients with castration-resistant prostate cancer at high risk for developing bone metastases as indicated by a PSA value of at least 8.0 ng ml -1 within 3 months before randomization and/or a PSA doubling time of 10.0 months or less. Interestingly, although denosumab significantly improved bone metastasis-free survival by approximately 4 months (P ¼ 0.028), no effects on progression-free or overall survival were observed.
Although the safety profiles of the two agents were relatively similar in the head-to-head trial, 78 a slightly higher incidence of new primary malignancies and hypocalcemia was recorded in patients treated with denosumab. In addition, it should be noted that the longterm safety of denosumab is not known. Thus, it is likely that treatment choices in this patient population may be driven primarily by safety considerations.
Conclusion
BPs have been used extensively in combination with standard anticancer therapy, and the feasibility and safety of concomitant dosing is well established. Emerging evidence suggests that BPs may provide benefits beyond palliative effects and maintenance of bone health. Mechanistic evidence of the anticancer benefit of N-BPs, especially ZOL, is supported by preclinical data and by clinical observations from exploratory translational studies. The anticancer activity shown by ZOL includes inhibition of cancer cell proliferation, viability, motility, invasion and angiogenesis; induction of cancer cell apoptosis; and synergy with anticancer agents. As a result of multiple potential modes of Bisphosphonates as potential anticancer agents HK Koul et al anticancer activity, additional translational explorations are warranted to provide insight into the optimal combinations of agents to improve cancer-related outcomes. The role of BPs in the overall treatment strategies of patients with prostate cancer, as well as in other malignancies that place patients at risk for skeletal complications, will continue to evolve.
